Laevoroc Oncology Launches With Three-Pronged Strategy

Exclusive Interview With CEO Thomas Mehrling

24 May 2021

• By William Masters

Following early investor conversations, Laevoroc Oncology has split its leading products into three independent subsidiaries to off-set risk and provide greater choice to future partners. While there is no underlying platform technology, CEO Thomas Mehrling believes the subsidiaries all include potential “game-changing medicines.”

Laevoroc Offers More Choice To Investors • Source: Alamy

Zug, Switzerland-based Laevoroc Oncology is pursuing an unusual start-up structure, having established three independent subsidiaries, each containing an oncology asset. While Laevoroc Oncology has a controlling stake in each subsidiary, the groups can make independent financing and licensing agreements.

In Vivo spoke with co-founder and CEO Thomas Mehrling about the new company’s overall strategy, including future financing and potential...